Solubility enhancement has become a critical driver of modern drug development. For poorly soluble APIs, BCS Class II and IV compounds, and complex formulations, improving solubility ensures consistent absorption, reliable pharmacokinetics, and predictable clinical outcomes where standard formulation approaches often fail.
The strategic value is clear. Enhanced solubility enables lower doses, reduces variability across diverse patient populations, and accelerates regulatory submissions. It also supports efficient scale-up and global supply, an advantage for sponsors aiming to serve both established and emerging markets.
As pipelines increasingly include complex small molecules, hybrid APIs, and specialty formulations, solubility enhancement has become an essential downstream development capability for advanced CDMOs supporting drug product development and scale-up.
In this blog, we explore what solubility enhancement is, why it matters strategically, and how DRK Research Solutions applies these strategies within drug product development, technology transfer, and GMP manufacturing of finished dosage forms.
Key Takeaways:
- Solubility enhancement improves the absorption and bioavailability of poorly soluble APIs, supporting consistent clinical outcomes.
- Strategic selection of technologies such as ASD, nanoparticles, lipid-based systems, HME, and pH/ionisation ensures predictable performance from the lab to commercial scale.
- Early integration reduces formulation risk, preserves critical quality attributes, and accelerates regulatory submissions.
- CDMOs enable scalable, GMP-compliant processes while maintaining regulatory alignment and global supply readiness.
- Proactive solubility strategies lower development risk, improve dose efficiency, and enhance patient accessibility.
What Is Solubility Enhancement and Why Does It Matter in Modern Drug Development?
Solubility enhancement in pharmaceutical development refers to formulation-level strategies applied during drug product development. These approaches improve the dissolution and bioavailability of an Active Pharmaceutical Ingredient (API) without altering its chemical identity or engaging in API synthesis or manufacturing.
By improving dissolution behaviour early, solubility enhancement supports stable exposure, consistent dosing, and smoother progression from preclinical work to clinical development.
When applied correctly, it enables a drug product to dissolve predictably, absorb efficiently, and remain viable for downstream technology transfer and GMP manufacturing. Key approaches used in solubility enhancement are as follows:
- Solid Dispersion Techniques: Amorphous dispersions and polymer matrices increase surface interaction with the dissolution medium. This improves wettability and initial release without altering the API’s pharmacological profile.
- Lipid-Based Delivery Systems: Lipid carriers and self-emulsifying systems help overcome permeability limits. These platforms are suited for molecules intended for oral or parenteral delivery where solubility restricts bioavailability.
- Particle Size Reduction and Micronization: Reducing particle size increases surface area and accelerates dissolution at the point of administration. This method is effective when the solubility barrier is physical rather than chemical.
- Salt, Co-Crystal, and Complex Formation: Structural modification or co-former pairing increases solubility without reconstructing the core molecule. This is frequently used to align development with regulatory continuity and CMC predictability.
Solubility enhancement provides a structured route to stabilising performance across laboratory studies, clinical supply, and commercial manufacturing.
Why Do Pharma and Biotech Leadership Teams Prioritise Solubility Early?
Solubility enhancement supports both scientific continuity and commercial feasibility. For leadership teams, it reduces programme uncertainty, maintains regulatory defensibility, and protects against redevelopment at scale.
- Clinical Predictability: Improved dissolution supports consistent PK performance, reduces protocol adjustment pressure, and stabilises dose justification in early-phase trials.
- CMC and Tech Transfer Readiness: A solubility strategy prevents reformulation during scale-up and aligns analytical methods, stability data, and batch documentation for GMP environments.
- Manufacturing Continuity: Controlled dissolution behaviour ensures that equipment qualification, batch reproducibility, and release testing remain stable across facilities.
- Regulatory Alignment: Clear validation pathways and traceable data records support EMA and FDA expectations, improving submission strength and audit preparedness.
Solubility enhancement moves dissolution control from a recurring obstacle to a reliable component of programme strategy, enabling a more stable path from development to market supply.
How Do CDMOs Reduce Development and Regulatory Risk Through Solubility Enhancement?
Regulatory assessment of solubility enhancement approaches focuses on scientific justification, validated analytical data, and consistency across development and manufacturing. Supporting data must demonstrate stability, reproducibility, and performance in line with EMA, FDA, and ICH requirements.
Solubility challenges remain a top cause of delays and reformulations in pharmaceutical pipelines, particularly for BCS Class II and IV compounds. Partnering with a CDMO allows sponsors to address these challenges early, transforming solubility enhancement from a reactive experiment into a proactive development strategy.
Key impacts of strategic CDMO-led solubility enhancement:
- Minimise Reformulation Risk: Prevent late-phase failures by optimising solubility at the pre-formulation and formulation design stages.
- Preserve Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs): Maintain formulation integrity during scale-up and tech transfer to GMP production.
- Ensure Regulatory Readiness: Generate submission-ready analytical and stability data aligned with EMA, FDA, and ICH expectations.
With this approach, solubility enhancement becomes a controlled, measurable decision rather than an unpredictable experimental step, supporting clinical continuity, regulatory confidence, and global market readiness.
Best 10 Solubility Enhancement Technologies Applied by Leading CDMOs in 2026
Leading CDMOs employ a range of advanced solubility enhancement technologies, and these strategies are selected based on formulation feasibility, manufacturability, and regulatory expectations. The goal is to improve dissolution performance while maintaining process robustness and compliance throughout the product lifecycle.
The following sections detail the key technologies and the value CDMOs bring to drug developers.
1. Amorphous Solid Dispersions (ASD)
Amorphous solid dispersions convert crystalline APIs into high-energy amorphous forms, dramatically increasing dissolution rate and oral bioavailability. This technology is particularly valuable for poorly soluble BCS Class II and IV compounds, where conventional formulation approaches fail.
Where a CDMO adds value
- Polymer/API compatibility mapping (PVP, HPMC-AS, copovidone) to ensure chemical and physical stability
- Maintenance of critical quality attributes (CQAs) during tech transfer, including glass transition temperature and residual solvent monitoring
- Predictive risk modelling to prevent recrystallisation during storage and shipment
Outcome for drug programmes
- Faster attainment of target plasma concentrations in early-phase studies
- Reduced variability across diverse patient populations with varying dietary and metabolic baselines
- High-quality, submission-ready data supporting EMA/FDA filings
2. Nanoparticle Technology & NanoSol Platforms
Nanoparticulation enhances API surface area, accelerating dissolution for poorly soluble compounds. CDMOs apply nanoparticle approaches to reduce clinical variability and optimise dosage for global distribution.
Execution levers used by CDMOs
- Wet media milling and high-pressure homogenisation for precise particle control
- Nano-suspension stabilisation to maintain shelf life under varied storage conditions
- Scale-up protocols preserving critical process parameters (particle size distribution, zeta potential, polydispersity)
Strategic benefit
- Potential for earlier dose reductions, reducing the cost of goods (CoGs)
- Minimised formulation drift during international cold-chain transit
- Predictable analytical profiles enhancing regulatory confidence
3. Lipid-Based Formulations (LBF)
Lipid-based formulations, including SEDDS and SMEDDS, enable efficient solubilisation and absorption of lipophilic APIs. They are often applied in early-phase bioavailability rescue projects for compounds with poor water solubility.
CDMO applications
- Custom SEDDS/SMEDDS system design for target absorption profiles
- modelling digestive pathways to account for variable GI environments.
- Compatibility testing with softgel, capsule, and oral suspension formats
Programme impact
- Consistent absorption across diverse patient populations
- Reduced risk of formulation failure during scale-up and commercial production
- Greater confidence in global launch timelines
4. Spray Drying Technology
Spray drying is a controlled particle engineering method that enables consistent amorphous conversion, which is critical for poorly soluble APIs and complex formulations.
Why CDMO competency matters
- Closed-loop solvent recovery ensures GMP compliance and environmental safety
- Comprehensive feed solution characterisation supports regulatory submissions
- Real-time PAT monitoring minimises batch rejection and ensures reproducibility
Outcome
- Accelerated development timelines
- Transferable master batch records for multi-site manufacturing
- Reliable scale-up with minimal risk to CQAs
5. Hot Melt Extrusion (HME)
HME enables continuous processing for APIs stable at high temperatures, creating uniform dispersions with enhanced solubility and bioavailability.
Execution parameters
- Polymer selection to retain supersaturation after administration
- Inline monitoring of torque and melt pressure to stabilise critical process parameters
- Regulatory-ready documentation for EMA, FDA, and ANVISA submissions
Operational relevance
- Supports continuous manufacturing trends, reducing overall CapEx
- Streamlines scale-up into emerging markets with predictable quality
- Minimises formulation redevelopment during commercial transition
6. pH Modification & Ionisation Strategies
Optimising API ionisation and microenvironmental pH can significantly improve solubility while maintaining regulatory compliance. This foundational strategy is embedded in both CMC planning and downstream tech transfer.
What CDMOs do differently
- Ionisation constant modelling with microenvironmental pH control
- Salt form screening to ensure manufacturability and long-term stability
- Excipient selection guided by import availability
Result
- Predictable dissolution profiles supporting global filings
- Reduced post-approval variation risk
- Lower risk of clinical or commercial setbacks
7. Solid Solutions & Co-Precipitates
Solid solutions stabilise amorphous APIs without heavy reliance on polymers, improving manufacturability and long-term storage performance.
ICP value
- Balances solubility enhancement with practical manufacturing constraints
- Reduces sensitivity to humidity and packaging conditions
- Extends product stability in hot and humid climates.
8. Cyclodextrin Complexation
Cyclodextrin inclusion complexes improve aqueous solubility for APIs, offering flexibility in formulation design for both oral and parenteral dosage forms.
Application scope
- Oral liquids tailored for paediatric and geriatric populations
- Injectable solubility enhancement without toxic solvent burden
- Reduced irritation for parenteral administration
9. Predictive Modelling & Computational Screening
Advanced modelling shifts solubility enhancement from trial-and-error to regulatory-focused design, enabling strategic, cost-efficient development.
Core elements
- Solubility parameter prediction (Hansen, COSMO-RS)
- Early thermodynamic failure detection to protect budgets
- CQA mapping to clinical endpoints for regulatory defensibility
Executive takeaway
- Mitigates clinical failure risks before formulation is finalised
- Supports rapid global deployment
- Increases confidence for leadership in strategic CMC decisions
10. Integrated Multi-Technology Platform Approach
Leading CDMOs provide integrated downstream pathway support, combining multiple solubility technologies with GMP drug product manufacturing and regulatory readiness.
Integrated execution chain
- Pre-formulation assessment and platform selection (ASD, nano, lipid, HME, hybrid)
- GMP manufacturing and scale-out
- Regulatory documentation and inspection readiness
- Commercial supply with affordability considerations
Why it matters for buyers
- One partner, fewer handoffs, and streamlined accountability
- Clinical continuity without reformulation risks
- Predictable timelines, validated supply chains, and audit resilience
Technology Selection: A CDMO Decision Matrix for Executives
Selecting the right solubility enhancement technology is a pivotal decision for pharmaceutical executives. The choice directly affects clinical performance, regulatory approval timelines, manufacturing scalability, and commercial success.
Before committing to a technology, leaders must consider:
- The intrinsic properties of the API, including solubility, stability, and bioavailability.
- Regulatory precedent and the likelihood of EMA/FDA acceptance.
- The commercial impact, including scalability, cost of goods, and accessibility for global markets,
The table below illustrates how different technologies match specific API challenges and programme goals.
| Technology | Primary Use Case | Regulatory Strengths | Commercial Relevance |
| Amorphous Solid Dispersions (ASD) | APIs with low dissolution rates | Established EMA/FDA acceptance; extensive precedent in submissions | Easily scalable from lab to commercial scale; supports multiple dosage forms |
| Nanoparticles & NanoSol Platforms | Ultra-low solubility APIs (<10 µg/mL) | Strong bioavailability enhancement data supporting regulatory filings | Enables dose reduction, lowering the cost of goods (CoGs); improves accessibility |
| Lipid-Based Formulations (LBF) | Lipophilic APIs and lymphatic-targeted compounds | Demonstrated biorelevance across variable GI conditions; precedents in regulatory filings | Compatible with softgels, capsules, and oral liquids; stabilises absorption in diverse populations |
| Hot Melt Extrusion (HME) | Thermally stable APIs benefiting from continuous processing | Continuous manufacturing aligns with GMP expectations; transferable CPP documentation | Enables seamless scale-up, minimises reformulation risk, and reduces CapEx for commercial supply |
How Solubility Enhancement Accelerates Clinical Milestones?
By proactively addressing solubility during early development, CDMOs help sponsors reduce technical risk, maintain critical quality attributes, and ensure consistent performance across diverse patient populations.
This approach directly influences clinical outcomes, regulatory efficiency, and global market readiness.
Key Impacts on Clinical Progression
- Higher probability of meeting PK endpoints in Phase I/II: optimised dissolution and absorption profiles enable predictable pharmacokinetics, reducing variability between subjects and trial sites.
- Lower inter-subject variability: Accounting for dietary and metabolic differences in diverse regions, solubility enhancement ensures consistent exposure and efficacy, supporting broader inclusion in global trials.
- Reduced dose and improved safety profile: Enhanced bioavailability allows dose reduction, lowering the risk of serious adverse events (SAEs) and minimising patient discontinuation.
- Fewer formulation changes: By integrating solubility optimisation early, reformulation is minimised, shortening submission cycles and accelerating regulatory approval timelines.
- Outcome: Predictable clinical-to-commercial progression: Strategic solubility management transforms a high-risk development programme into a controlled, scalable pathway, enabling sponsors to move efficiently from early-phase trials to commercial supply without compromising quality or regulatory compliance.
How DRK Research Solutions Advances Solubility Enhancement in Pharmaceutical Development?
DRK Research Solutions applies solubility enhancement strategies within its CDMO framework to support drug product development, scale-up, and GMP manufacturing. The focus remains on formulation design, analytical validation, and process transfer to ensure predictable performance from early development through commercial supply.
- Comprehensive Development Support: Solubility enhancement programs are built on tailored formulation design, analytical method optimisation, and pre-formulation evaluation. This ensures that solubility gains are scientifically justified, reproducible, and capable of supporting downstream manufacturing and stability requirements.
- GMP Manufacturing Across Multiple Sites: Manufacturing activities are supported through EU-approved partner facilities in Europe and Asia operating under EU and US-aligned CGMP standards.
- Expertise in High-Value and Complex Molecules: DRK supports drug product development for challenging APIs, including Biopharmaceutics Classification System Class II and IV compounds, with drug substances sourced through qualified suppliers and approved vendor partners.
- Regulatory-Ready Documentation: Each program is supported by submission-ready eCTD documentation, including stability studies and solubility data packages aligned with EMA, FDA, and other global regulatory expectations.
- Flexible Production Options: Batch sizes and production models are configured to support both clinical trial supply and commercial manufacturing, without requiring process changes or vendor transitions as programs progress.
DRK does not manufacture drug substances (APIs); instead, APIs are sourced through qualified supplier and approved vendor networks, while DRK focuses exclusively on downstream drug product development and GMP manufacturing.
This integrated CDMO model enables sponsors to address solubility constraints, reduce development and regulatory risk, and achieve predictable formulation performance from early development through commercial supply.
Conclusion
Well-executed solubility enhancement at the drug product level reduces development risk, supports regulatory confidence, and enables scalable, compliant manufacturing. When integrated early and carried through to commercial supply, these strategies help sponsors maintain performance consistency across the product lifecycle.
DRK Research Solutions delivers this through integrated drug product formulation development, technology transfer, and GMP-compliant manufacturing of finished dosage forms. By using advanced solubility technologies, robust analytical validation, and regulatory-ready documentation, DRK Research Solutions helps sponsors minimise risk, maintain critical quality attributes, and ensure predictable global supply.
Ready to advance your drug programme with proven solubility enhancement expertise? Connect with DRK Research Solutions CDMO team to explore your next project.
FAQs
1. What does solubility enhancement mean in drug development?
Solubility enhancement refers to strategies and technologies used to improve the aqueous solubility of poorly soluble drugs, enabling better absorption, efficacy, and consistent clinical performance.
2. Why is improving drug solubility important for clinical outcomes?
Poorly soluble drugs can lead to unpredictable absorption, higher inter-subject variability, and delayed regulatory approval. Enhancing solubility ensures consistent dosing, reliable pharmacokinetics, and smoother clinical progression.
3. Which solubility enhancement techniques are commonly used?
Techniques include amorphous solid dispersions, nanoparticles, lipid-based formulations, hot melt extrusion, pH modification, and cyclodextrin complexation, each selected based on API properties and clinical goals.
4. What regulatory expectations exist for solubility-enhanced formulations?
Regulators require validated methods, robust stability data, characterisation of critical quality attributes, and clear documentation of formulation and manufacturing processes to ensure safety, efficacy, and reproducibility.
5. What challenges do pharmaceutical teams face with solubility enhancement?
Challenges include API-excipient compatibility, maintaining critical quality attributes during scale-up, preventing recrystallisation, and ensuring reproducible dissolution profiles. Experienced CDMOs help mitigate these risks efficiently.